Premium
Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma
Author(s) -
Brown Zachary J.,
Cloyd Jordan M.
Publication year - 2021
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26384
Subject(s) - medicine , pancreatic ductal adenocarcinoma , neoadjuvant therapy , pancreatic cancer , adenocarcinoma , receipt , oncology , pancreatectomy , general surgery , resection , cancer , surgery , breast cancer , world wide web , computer science
For patients with localized pancreatic cancer, neoadjuvant therapy (NT) is increasingly delivered before surgery to maximize the receipt of multimodality therapy and the odds of a margin‐negative resection. Three decades of refining the use of NT have led to its acceptance as a valid treatment approach for pancreatic adenocarcinoma. In this review, we discuss the rationale for and recent global trends in the utilization of NT for patients with pancreatic cancer.